These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1251 related items for PubMed ID: 34059019

  • 1. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X, Wang P, Qiao Q, Jiang Y.
    BMC Cancer; 2021 May 31; 21(1):646. PubMed ID: 34059019
    [Abstract] [Full Text] [Related]

  • 2. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q, Shou J, Ying J, Ling Y, Yu Y, Shen Z, Zhang Y, Li N, Shi Y, Zhou A.
    Future Oncol; 2021 Aug 31; 17(22):2893-2905. PubMed ID: 34189951
    [Abstract] [Full Text] [Related]

  • 3. TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.
    Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC.
    Cancer Lett; 2021 Feb 28; 499():137-147. PubMed ID: 33249194
    [Abstract] [Full Text] [Related]

  • 4. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y, Huang Z, Cai J, Tang P, Zhang F, Tan M, Shen B.
    Aging (Albany NY); 2020 Dec 19; 13(2):2780-2802. PubMed ID: 33408272
    [Abstract] [Full Text] [Related]

  • 5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z, He B, Cai Q, Zhang P, Peng X, Zhang Y, Xie H, Wang X.
    Int Immunopharmacol; 2021 Sep 19; 98():107807. PubMed ID: 34175739
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, Yang Z, Li R, Xue Q, Gao S, He J.
    Front Immunol; 2021 Sep 19; 12():669750. PubMed ID: 34054840
    [Abstract] [Full Text] [Related]

  • 7. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B, Park JH, Ren L, Yew PY, Kiyotani K, Antic T, O'Connor K, O'Donnell PH, Nakamura Y.
    Cancer Rep (Hoboken); 2018 Jun 19; 1(1):e1002. PubMed ID: 32729250
    [Abstract] [Full Text] [Related]

  • 8. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K, Hu M, Chen J, Wei J, Qin J, Lin S, Du H.
    Int J Mol Sci; 2021 May 13; 22(10):. PubMed ID: 34068143
    [Abstract] [Full Text] [Related]

  • 9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.
    Gut; 2019 Sep 13; 68(9):1653-1666. PubMed ID: 30902885
    [Abstract] [Full Text] [Related]

  • 10. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
    Wu T, Tang C, Tao R, Yong X, Jiang Q, Feng C.
    Front Immunol; 2021 Sep 13; 12():693881. PubMed ID: 34552581
    [Abstract] [Full Text] [Related]

  • 11. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J, Lun L, Jiang X, Wang Y, Li X, Du G, Wang J.
    Int Immunopharmacol; 2021 Aug 13; 97():107675. PubMed ID: 33964809
    [Abstract] [Full Text] [Related]

  • 12. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 13. A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology.
    Shadbad MA, Asadzadeh Z, Hosseinkhani N, Derakhshani A, Alizadeh N, Brunetti O, Silvestris N, Baradaran B.
    Front Immunol; 2021 May 01; 12():734956. PubMed ID: 34603316
    [Abstract] [Full Text] [Related]

  • 14. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W, Zhu D, Wang C, Zhu Y.
    Cancer Med; 2020 Apr 01; 9(8):2774-2790. PubMed ID: 32096345
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
    Li J, Yin L, Chen Y, An S, Xiong Y, Huang G, Liu J.
    Int J Med Sci; 2021 Apr 01; 18(14):3150-3157. PubMed ID: 34400885
    [Abstract] [Full Text] [Related]

  • 20. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK.
    Int J Mol Sci; 2021 Apr 29; 22(9):. PubMed ID: 33946835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.